



INNOVATION FOR
GOOD HEALTH

FOSUN PHARMA

CONTENTS

- 02 ABOUT FOSUN PHARMA
- 16 INNOVATIVE R&D
- 26 GLOBAL BUSINESS LANDSCAPE
- 28 INTEGRATED DEVELOPMENT
- 36 CORPORATE SOCIAL RESPONSIBILITY



ABOUT FOSUN PHARMA

Founded in 1994, [Shanghai Fosun Pharmaceutical \(Group\) Co., Ltd.](#) ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well as central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of "innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

OUR MISSION, VISION AND VALUES

Our Mission

Better Health for Families Worldwide

Our Vision

We are committed to becoming a first-class enterprise in the global medical and health market

Our Values



Care for Life



Continuous
Innovation



Pursuit of
Excellence



Sustainable
Partnership

OUR CORPORATE STRATEGY AND DEVELOPMENT MODEL




INnovation

INternationalization


INtelligentization

INtegration

Our Development Model



OUR INNOVATION MILESTONES



Board of Directors



Mr. Wu Yifang
Executive Director,
Chairman



Mr. Wang Kexin
Executive Director,
Co-Chairman



Ms. Guan Xiaohui
Executive Director,
Vice Chairman



Mr. Wen Deyong
Executive Director,
Chief Executive Officer(CEO)



Mr. Chen Qiyu
Non-Executive Director



Mr. Yao Fang
Non-Executive Director



Mr. Xu Xiaoliang
Non-Executive Director



Mr. Pan Donghui
Non-Executive Director



Ms. Li Ling
Independent Non-
Executive Director



Mr. Tang Guliang
Independent Non-
Executive Director



Mr. Wang Quandi
Independent Non-
Executive Director



Mr. Yu Tze Shan Hailson
Independent Non-
Executive Director

Board of Supervisors



Ms. Ren Qian
Chairman of the Supervisory
Committee



Mr. Cao Genxing
Supervisor



Mr. Guan Yimin
Supervisor

*As of September 30, 2022

Management Team



Mr. Wen Deyong
Executive Director,
Chief Executive Officer (CEO)



Mr. Chen Yuqing
Co-Chief Executive Officer (Co-CEO),
Chairman of Shanghai Fosun Health
and Technology(Group)Co.,Ltd



Ms. Mei Jingping
Executive President,
Chief Strategy Officer (CSO)



Mr. Li Shengli
Executive President, Chief Growth
Officer (CGO), CEO of Shanghai
Fosun Health and
Technology(Group)Co.,Ltd



Mr. Wang Donghua
Senior Vice President



Mr. Li Dongjiu
Senior Vice President



Ms. Feng Rongli
Senior Vice President,
General Manager of Human
Resources Department



Mr. Liu Yi
Senior Vice President,
Chairman and CEO of Medical
Devices Division



Mr. Hu Hang
Senior Vice President, President
of Shanghai Fosun Health and
Technology(Group)Co.,Ltd



Mr. Bao Qingui
Senior Vice President,
Chairman of Medical
Diagnosis Division



Ms. Li Jing
Senior Vice President,
President of Established Medicines
Manufacturing & Supply Division



Mr. Rong Yang
Senior Vice President,
CEO of Fosun Pharma USA Inc.



Ms. Dong Xiaoxian
Vice President, Secretary of the
Board, Joint Company Secretary,
Director of Office of Secretary
of the Board



Mr. Zhang Yuejian
Vice President,
President of Medical
Diagnostics Division



Mr. Yuan Ning
Vice President,
Co-Chief Business Development
Officer (Co-CBO),
General Manager of Business
Development Department



Ms. Su Li
Vice President,
Executive President of
Established Medicines
Manufacturing & Supply Division



Mr. Ji Hao
Vice President,
General Manager of Anti-Corruption &
Supervision Department




Ms. Zhu Yue
Vice President,
General Manager of
the Legal Department

*As of September 30, 2022

FY2021 Revenue:
RMB39,005 million


Increase of
28.70% YoY



FY2021 Net profit attributable
to shareholders of the
listed company:

RMB 4,735 million


Increase of
29.28% YoY




FY2021 Net profit
(after extraordinary gain or loss)
attributable to shareholders of the
listed company:

RMB3,277 million

Increase of
20.60% YoY



*As of December 31, 2021 Unit: RMB million



FY2021 R&D expenditure :
RMB4,975 million


Increase of 24.28% YoY



2,800+ staff in the R&D team,

including 1,500+ staff with master's
degrees or higher

* Unit: RMB million



Top 10

among China's top 100 Pharmaceutical Companies (MIIT)

Five-star (Excellent)

CSR Report 2021 rating

A

MSCI ESG rating



Employees worldwide:
36,604



6,900+ staff
in the commercialization team

*As of June 30, 2022



INNOVATIVE RESEARCH & DEVELOPMENT


Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.




As at the end of June 2022, Fosun Pharma had more than 2,800 R&D personnel, of which over 1,500 persons obtained a master's degree or above. More than 260 pipeline projects, including innovative drugs, biosimilars, generic drugs and consistency evaluation items are under research

Continuously Increasing R&D Investment

- In 2021, the annual R&D expenditure was RMB4,975 million, representing an increase of 24.28% YOY
- In the first half of 2022, R&D expenditure was RMB2,399 million, representing an increase of 22.77% YOY




- In the first half of 2022, the R&D expenditure of the pharmaceutical segment was RMB2,062 million, representing an increase of 16.04% YOY
- R&D investment in pharmaceutical segment accounted for 14.39% of the revenue from pharmaceutical manufacturing segment



Open R&D Ecology



Core Therapeutic Areas



Innovation Achievements Continued To Benefit More Patients

After over a decade of continuous investment, many varieties such as Han Li Kang (Rituximab Injection), Han Qu You (Trastuzumab Injection), Su Ke Xin (Avatrombopag Maleate Tablets), COMIRNATY® (in Hong Kong SAR, Macau SAR and Taiwan region) and Han Si Zhuang (Serplulimab Injection) have been approved and sold in large quantities in the past three years, accelerating the implementation of innovative R&D and driving sustainable growth in the Group's performance. In the first half of 2022, the revenue from new and sub-new products accounted for over 25% of the revenue in the pharmaceutical segment

● Artesun® (Artesunate for Injection)

China's No.X-01 New Drug, saved more than 48 million lives of severe malaria patients



● COMIRNATY® (mRNA COVID-19 vaccine, also known as BNT162b2)

The world's first mRNA COVID-19 vaccine fully approved by FDA



● Han Li Kang (Rituximab injection)

The first biosimilar product approved in China



● Jie Bei An (Azulfidine Tablets)

The first domestic small molecule anti Covid-19 oral drugs



● Han Qu You (Trastuzumab Injection)

The first domestic trastuzumab biosimilar approved for launch both in China and the EU



● Su Ke Xin (Avatrombopag Maleate Tablets)

The first small-molecule innovative drug introduced



● Han Si Zhuang (Serplulimab injection)

The first self-developed innovative monoclonal antibody



● Akynzeo (Netupitant and Palonosetron Hydrochloride Capsules)

The World's first and only oral combination anti-emetic preparation that synergically blocks two key CINV receptor pathways (5-HT3 and NK1)



● Yi Kai Da (Ejilunsai Injection)

The first CAR-T cell therapy product approved for launch in China



● Otezla (Apremilast Tablets)

The first and only orally-administered phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis in China



*As of 30 June 2022

IN-HOUSE R&D

BIO-MEDICINE CORE PIPELINE

IN-HOUSE R&D

HENLIUS



Henlius (02696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. As of August 29, 2022, 5 products have been launched in China, 1 approved for marketing in overseas markets, 13 indications approved worldwide, and 5 New Drug Applications (NDAs) accepted for review in China. Since its inception in 2010, Henlius has built an integrated

biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practices (GMPs), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP.

5
Products launched
in China



HANLIKANG
(rituximab)



HANQUYOU
(trastuzumab)



HANDAYUAN
(adalimumab)



HANBEITAI
(bevacizumab)



HANSIZHUANG
(serplulimab)

1
Product launched
abroad

HANQUYOU (Zercepac® in Europe
Tuzucip® and Trastucip® in Australia)



20+
Clinical studies

70+
Clinical approvals

5
NDAs accepted
for review

13+11
Candidates / Combo
Therapies under Clinical Studies

13
Indications launched

Major
therapeutic
areas



oncology



autoimmune
diseases



ophthalmic
diseases

48,000L

Commercial Capacity
Currently

	Products	Targets	Indications	Pre-clinical	IND	Phase I	Phase II	Phase III	NDA
Near Commercialization	HLX10 ⁽¹⁾ (Slulizumab)	+chemo	PD-1	Squamous non-small cell lung cancer 1L	International multi-centre clinical study				
				Extensive-stage small cell lung cancer 1L	International multi-centre clinical study				
Under Clinical Studies	HLX10 ⁽¹⁾ (Slulizumab) Xkbio	+chemo	PD-1	Neo-adjuvant treatment of gastric cancer					
		+chemo +radio	PD-1	Limited-stage small cell lung cancer 1L	International multi-centre clinical study				
		+HANBEITAI	PD-1+VEGF	Non-squamous non-small cell lung cancer 1L					
				Hepatocellular carcinoma 1L					
				Metastatic colorectal cancer 1L					
		+HLX07	PD-1+EGFR	Squamous cell carcinoma of head&neck 2L					
	HLX04-O ⁽³⁾	+HLX26	PD-1+LAG-3	Solid tumors					
		+HLX60 ⁽²⁾	PD-1+GARP	Solid tumors					
				Wet age-related macular degeneration	International multi-centre clinical study				
	HLX11(Patuximab) ⁽⁴⁾	ESSEX/ORGANON	HER2	Breast Cancer					
	HLX14 (Disulfiramab) ⁽⁵⁾	ORGANON	RANKL	Osteoporosis					
	HLX22 + HANQUYOU		HER2+HER2	Gastric cancer					
	HLX07 ⁽⁶⁾		EGFR	Solid tumours (non-small cell lung cancer, esophageal carcinoma, etc.)					
	HLX05 (Cetuximab) ⁽⁷⁾	Singze	EGFR	Metastatic colorectal cancer, squamous cell carcinoma of the head and neck					
	HLX12 (Ramulizumab)		VEGFR2	Gastric cancer, non-small cell lung cancer, metastatic colorectal cancer					
	HLX26		LAG-3	Solid tumors, lymphomas					
	HLX35 ⁽⁸⁾	BINACEA	EGFRx 4-1BB	Solid tumors					
	HLX301 ⁽⁹⁾		PD-L1x TIGIT	Solid tumors					
	HLX13 (Eplimubab)		CTLA-4	Melanoma, renal cell carcinoma, metastatic colorectal cancer					
	HLX15 (Daretuzumab)		CD38	Multiple myeloma					
	HLX23 ⁽¹⁰⁾		CD73	Solid tumors					
	HLX53		TIGIT	Solid tumors, lymphomas					

(1) Clinical approvals obtained in China/the US/the EU countries, etc.

(2) Clinical Trial Notification has been acknowledged by the Therapeutic Goods Administration in Australia.

(3) Clinical approvals obtained in China/Australia/the US/Singapore/the EU countries, etc.

(4) Global commercialisation rights excluding Chinese mainland, Hong Kong, Macao and Taiwan region granted to Organon.

(5) Global commercialisation rights excluding Chinese mainland, Hong Kong, Macao and Taiwan region granted to Organon. Clinical Trial Notification has been acknowledged by the Therapeutic Goods Administration in China and Australia.

(6) Clinical approvals obtained in China/the US.

(7) Commercialisation rights in China have been granted to Shanghai Jingze.

(8) Global commercialisation rights excluding Chinese mainland, Hong Kong, Macao and Taiwan region granted to Binacea

(9) Clinical Trial Notification has been acknowledged by the Therapeutic Goods Administration in China and Australia

(10) Clinical approvals obtained in the US

* last update on 29th August 2022

IN-HOUSE R&D

INNOVATIVE SMALL MOLECULE CORE PIPELINE

FOCHON
PHARMACEUTICALS



Established by a joint venture between Fosun Pharma and overseas scientists, Fochon is a high-tech enterprise dedicated to the research and development of new small-molecule targeted new drugs with independent intellectual property rights, with an international layout of "two countries and three places" in Chongqing, Shanghai and San Francisco.

Pipeline candidates: **FCN-437c** (**CDK4/6**) is in Phase III clinical trial , **FCN-159 (MEK)** clinical trial is in progress in China, U.S. and Europe; The right outside of Chinese Mainland, Hong Kong and Macau of **FCN-338 (BCL-2)** was granted to Lilly.

Therapeutic Areas	Project	Target	Indications	Pre-clinical	IND	Phase I	Phase II	Phase III	NDA
Oncology	FCN-437c	CDK4/6	Breast Cancer(1L)	Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S.					
			Breast Cancer(2L)	Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S.					
	SAF-189	ALK	Non-small cell lung cancer	Initiated Phase 3 clinical trial in Chinese Mainland in January 2022; approved to enter clinical trials by FDA					
		ROS1	Non-small cell lung cancer	Approved to enter clinical trials by FDA					
	HLX-208	BRAF V600E	Metastatic colorectal cancer, non-small cell lung cancer and other solid tumors	Approved to enter Phase 2 clinical trials by NMPA in January 2022					
			LCH and ECD	Approved to enter Phase 2 clinical trials by NMPA in January 2022					
	FCN-159	MEK	Neurofibroma type I	International multi-center clinical trial					
			Low-grade glioma						
			Malignant melanoma						
			Arteriovenous malformation	Approved to enter clinical trial by NMPA in May 2022					
			Histiocytic tumors	Approved to enter clinical trial by NMPA in May 2022					
	ORIN1001	-	Solid tumors						
	YP01001	VEGFR	Advanced solid tumors	Approved Phase 1 clinical trial in the U.S.					
	FCN-338 ¹	BCL-2	Hematologic malignancies	Approved Phase 1 clinical trial in the U.S.					
			Relapsed or refractory B-cell lymphoma	Approved to enter Phase 1 clinical trial by NMPA in October 2021					
	FH-2001	FGFR/PD-L1	Solid tumors such as liver cancer	Approved to enter Phase 1 clinical trial by NMPA in August 2021					
	PLK1 inhibitor	PLK1	KRAS mutations in colorectal cancer and non-small cell lung cancer						
	CHK1 inhibitor	CHK1	Ovarian cancer and other related solid tumors						
	IRAK4/BTK dual target inhibitor	IRAK4/BTK	Diffuse large B-cell lymphoma (DLBCL)						

FOSUN
ORINOVE



Established by Fosun Pharma and a team of overseas scientists, Fosun Orinove focuses on cancer cell metabolism-related small-molecule anticancer drugs that have novel targets, mechanisms and structural chemical identities. It has set up R&D bases in Suzhou and Los Angeles.

Pipeline candidate Orin1001 is with novel target, MOA and compound.

Therapeutic Areas	Project	Target	Indication	Pre-clinical	IND	Phase I	Phase II	Phase III	NDA
Central Nervous System	Opicapone Capsules	COMT	Parkinson's syndrome	Launched in Europe*					
Blood System	Avatrombopag tablets	TPO-R	Chronic immune thrombocytopenia (ITP)						
	Tenapanor Tablet	NHE 3	End-stage Renal Disease – Hemodialysis						
Metabolism and Digestive System	Ferric pyrophosphate citrate solution	-	Iron replacement for HD patients						
	Tenapanor Tablet	NHE 3	Irritable Bowel Syndrome with Constipation						
	FCN-342	URAT1	Gout	Granted Phase 1 clinical trial by NMPA in November 2021					
Anti-infection	Molnupiravir	RNA Polymerase	Treatment of COVID-19						
	Paxlovid	3CL Protease	Treatment of COVID-19						
	mRNA vaccine BNT162b2	-	Prevention of novel coronavirus pneumonia	Chinese Mainland: Phase II clinical trial completed; Hong Kong SAR: Authorized for emergency use; Macau SAR: Obtained advance permission as an imported vaccine; Taiwan region: Obtained special approval for emergency use					
	PA-824	-	Extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) that is intolerant of treatment/ineffective	Launched Pretomanid in the U.S.*					
Others	Fortacin spray (lidocaine proparacaine spray)	-	Premature ejaculation	Launched in Europe*					
	ET-26	-	Anesthesia						
	ORIN1001	-	Idiopathic pulmonary fibrosis	Approved to enter Phase 2 clinical trial by NMPA in July 2022; Phase I clinical trial in the U.S.*					
	FCN-016	ROCK	Glaucoma						
	Coagulation factor FXLa inhibitor	FXLa	Anti-thrombotic						
	FH2002	Complement Factor B	IgA nephropathy and other immune abnormalities						

LICENSE-IN & LICENSE-OUT



License-in

Su Ke Xin (Avatrombopag Maleate tablets)

- The first innovative small molecule drug introduced
- Approved by NMPA for marketing in 2020
- The world's first and only oral-use tablet approved to treat low blood platelet count in adults with long-lasting (chronic) liver disease (CLD), bringing a leading global clinical treatment option for Chinese patients with CLD related thrombocytopenia
- Included in NRDL in China in Dec. 2020 which came effective in March 2021, to improve the accessibility of clinical treatment for patients
- Revenue of RMB360 million in the first half of 2022



Long-lasting DaxibotulinumtoxinA Product - RT002

- Licensed in the first long-lasting DaxibotulinumtoxinA product in Chinese Mainland, Hong Kong and Macau
- Completed enrollment of Phase 3 clinical study in China for the treatment of moderate-to-severe glabellar lines (aesthetic indication) and for cervical dystonia (therapeutic indication)
- Safety: formulated without human blood-derived products or manufactured using animal-derived proteins. 3,800+ cases showed no severe adverse events
- Duration: median time is 24 weeks

License-out



● FCN-338

Fochon Pharma, a subsidiary of the company, granted Lilly the rights to develop, manufacture and commercialize BCL-2 inhibitor in regions except Chinese Mainland, Hong Kong and Macau for up to US\$440 million in license fees



● Han Qu You (Zercepac)

Henlius granted Intas Pharmaceuticals to exclusive commercializing Han Qu You (Zercepac) in the United States and Canada and granted Accord to exclusive commercialize Han Qu You (Zercepac) in Europe and part of the Middle East, North Africa region and the Commonwealth of Independent States. Zercepac (150mg) has been launched in nearly 20 European countries and regions including the UK, Germany, Spain, France, and Italy



● Han Da Yuan (Adalimumab)

Henlius granted Getz Pharma to commercialize Han Da Yuan in 11 countries in Asia, Africa, and Europe



● Han Si Zhuang (Serplulimab)

Henlius granted KG Bio to exclusive commercialize Han Si Zhuang (Serplulimab) in 10 countries in Southeast Asia



● Han Li Kang, Han Qu You, Han Bei Tai
Henlius granted Eurofarma, a leading local pharmaceutical company in Brazil, the rights to commercialize three products in 16 Latin American countries, including Han Li Kang (rituximab injection), Han Qu You (trastuzumab injection) and Han Bei Tai (bevacizumab injection), and actively expanding the market of the three products in Latin America



● HLX11、HLX14

Henlius granted Organon exclusive rights to commercialize two products, pertuzumab biosimilar HLX11 and denosumab biosimilar HLX14 worldwide except for China




COMIRNATY[®] (mRNA COVID-19 vaccine, also known as BNT162b2)

BIONTECH

FOSUN PHARMA
复星医药

In March 2020, Fosun Pharma has been licensed by BioNTech to exclusively develop and commercialize COVID-19 vaccines based on its mRNA technology platform in the Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.

Collaboration Milestones



Early-stage Investment & Deep Incubation

1. Early-stage Investment

- Participated in overseas healthcare professional funds for access to leading technologies globally with potential in-license and other collaboration



- Fosun Health Capital has completed financing as its first VC fund for innovative drugs
- Projects invested so far include Biomissile (bi-specific antibody) and Tianjin JuveStar (medical aesthetic)



2. Deep Incubation

FOSUN LEAD
复星领智

- Established in 2017, Fosun Lead focuses on the cutting-edge cross-fields of global biotechnology and information technology.
- Focusing on world-leading biotechnologies and information technologies, including precision repair technology for gene cell therapy, AI-assisting precision medicine for Oncology, personalized new antigen immunotherapy and intestinal microbial flora technology, etc.
- Presence in world-leading technology products, including portable MRI, handheld ultrasound device and Protein Sequencer, etc.

FUSION
复星医药 US Innovation Hub


- Fosun Pharma US Innovation Hub (FUSION BioVenture) is a platform under Fosun Pharma US in Boston.
- In 2019, Fusion incubated Archimmune Therapeutics which has two immuno-oncology platforms: personalized cancer vaccine (ACNP) and Multi-specific immuno-nano therapy (MINP).

CO-DEVELOPMENT

CAR-T Cell Therapy

FOSUNKite
复星凯特生物

In June 2021, Yi Kai Da (Ejilunsai injection) by Fosun Kite, a joint venture, became the first CAR-T cell therapy product approved for launch in China. It is mainly used for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after prior second-line or higher systemic therapy.





*Data as of September 30, 2022

GLOBAL BUSINESS LANDSCAPE

In the first half of 2022, revenue from regions outside Chinese Mainland and other countries amounted to RMB7,592 million, accounting for 35.58% of Fosun Pharma's total revenue, representing a period-on-period increase of 4.92 percentage points.

Revenue from countries and regions outside Chinese mainland in the first half of 2022

RMB7,592million
Total Revenue 35.58%
a period-on-period increase of 4.92 percentage points



Global Manufacturing System



Sublicensed from MPP to manufacture oral COVID-19 active pharmaceutical ingredient and the finished drugs from MSD and Pfizer with world-class manufacturing facilities and to commercialize in agreed low and middle income countries.

•Global Standard

•Over 10 production lines for API and formulation of Yao Pharma, Wanbang Biopharmaceuticals and Guilin Pharma received GMP certification for the U.S., Europe and other markets

•The production line of heparin sodium injection of Wanbang Biopharmaceuticals passed the on-site review by the FDA and is qualified to supply the U.S. market

•Gland Pharma received GMP certifications from the U.S., EU, Japan, Australia and other markets

•Improved Efficiency: from API to formulation

•Integration of manufacturing facilities to improve efficiency, accelerating the construction of Xuzhou and Chongqing comprehensive facilities and of API facilities in Changsha, Xuzhou and Chongqing

•Increased Biopharmaceutical Production Capacity

•Songjiang Facility Plant (1) received GMP certification, increased commercial production capacity from **24,000L to 48,000L**



Small Molecule API Small Molecule Formulation Biopharmaceutical

Global Commercialization System

•Commercialization Team



Domestic team: Innovative Products Team, BU Based Sales Team & New Retail Team



Overseas team : Africa, the U.S., and Other Markets



The Group had a commercialization team of over **6,900** employees, covering 40 Countries/Regions

More than **1,400** staff in the overseas commercialization teams

*As of June 30, 2022

•Overseas Commercialization Team

In the African Market

Business presence in 39 countries and regions; 800 frontline sales personnel to provide a one-stop service support system including registration, circulation, academic promotion, post-launch safety alert and other services

In the U.S. Market

Collaborated with 5 major wholesalers, 16 group purchasing organizations (GPOs) Through 21 distributors in the U.S. market and early 20 collaboration contracts covered 85% of the integrated network distribution system (IDNs), forming a multi-channel all-round coverage of the market.

INTEGRATED DEVELOPMENT

Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma actively promoted the integration of systems and resources in R&D, supply chain, manufacturing and commercialization to enhance synergies and operational efficiency and promote solid financial growth.

Pharmaceutical Manufacturing

- In the first half of 2022, the revenue from pharmaceutical manufacturing segment reached RMB14,327 million, up by 16.97% YOY.
- In the first half of 2022, the revenue from new and sub-new products accounted for over 25% of the revenue of the pharmaceutical manufacturing segment.

Fosun Pharma has a number of advantageous products for oncology and immunomodulation, anti-infection, metabolism and digestive system, central nervous system, and cardiovascular system.

Major products of oncology and immunomodulation



● **Han Li Kang**
(Rituximab injection)

The first biosimilar product approved in China

2021 sales
RMB 1,690 million

125.33% YoY

2022 H1 sales
revenue RMB
819 million



- **Han Qu You**
(Trastuzumab Injection)
- The first mAb product approved in both China and the EU



- **Su Ke Xin**
(Avatrombopag Maleate Tablets)

2021 sales revenue of RMB932 million

2022 H1 sales revenue RMB 813 million

2021 sales RMB426 million

2022 H1 sales revenue RMB 360 million.

Major products of anti-infection

- **mRNA COVID-19 vaccine**
By the end of February 2022, over 20 million doses of BNT162b2 have been administrated in Hong Kong SAR, Macau SAR, and Taiwan region, helping to establish the local COVID-19 immune barrier
- **Artesunate and other anti-malarial product**
have saved more than 48 million lives
- **SPAQ-CO® Disp for the prevention of malaria in children**
contribute to the effective reduction of incidence rate and mortality rate caused by malaria among children under 5 years old in Africa



Major products of central nervous system

- **Qi Wei** (quetiapine fumarate tablets)
- **Chang Tuo Ning** (penethyclidine hydrochloride injection)
- **Ao De Jin** (deproteinized calf blood serum injection)
- **Qi Cheng** (escitalopram oxalate tablets)



Major products of cardiovascular system

- **Heparin series preparations**
- **Bang Tan** (telmisartan tablets)
- **Bang Zhi** (pitavastatin calcium tablets)



Major products of metabolism and alimentary system comprise

- **Yi Bao**
(human erythropoietin for injection)
for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies was approved for launch in the Chinese Mainland
- **Atomolan tablets**
(glutathione tablets)
2021 sales over RMB500 million





MEDICAL DEVICES AND MEDICAL DIAGNOSIS

In the first half of 2022, the revenue from medical devices and medical diagnostics segment reached RMB**4,043** million, up by **42.51%** YoY.

Medical Devices

The medical devices segment of Fosun Pharma integrated several subsidiaries at home and abroad and has initially formed three major business divisions with medical aesthetics, respiratory health and professional medical care. It is committed to building a global leading operating platform for the medical device industry.



Medical Aesthetic







Respiratory Health



Professional Medical Device

1. Medical Aesthetic——Building a Wellness Ecosystem

Sisram Medical (01696.HK), the core platform for medical aesthetics, continues to build a wellness ecosystem through innovative product portfolio, diversified market strategy and global strategic layout, based on four core businesses lines of energy-based devices, injectables, aesthetics and digital dentistry, and personal care.

2022H1		FY2022H1 revenue US\$ 174.5 million, 39.3% YoY	Profit attributable to owners of the parent US\$ 20.5 million, 25.9% YoY	
Four Core Businesses	 Energy-based Devices Alma: The world's leading supplier of energy-based aesthetic medical devices	 Personal Care New personal care brand LMNT launched	 Aesthetics and Digital Dentistry Building the new dentistry platform	(IBSA, Raziell, Revance) Injectables The layout of injectable therapy

2. Respiratory Health

——Layout of Respiratory Health Ecological Industry

BREAS Fosun Pharma's medical devices segment continues to expand and enrich the respiratory product line. With 30 years of experience, Our Swedish professional mechanical ventilation company, Breas, provides innovative respiratory solutions to patients worldwide through three operating centers in Sweden, the United States and China.

In April 2021, focusing on Hainan's "Smart Manufacturing" strategy, the local manufacturing of Breas ventilators was launched and implemented. In March 2022, the localization project of Vivo3 / Vivo 45 was officially launched.



3. Professional Medical Device

——Providing solutions from pre-hospital care to hospital specialist solutions

In the field of professional medical devices, closely focusing on clinical needs, Fosun Med-tech provides total solutions from pre-hospital care to hospital surgery, covering first-aid units, medical equipment focusing on core tracks such as neurosurgery /orthopedics /oncology, high-end surgical robotic systems and medical consumables, the comprehensive layout of China's medical technology and service market.




















Da Vinci surgical robotic systems



As of June 30th 2022, nearly 300 Systems were installed in Chinese Mainland, Hong Kong and Macau and completed more than 250,000 surgeries. 7,135 systems were installed worldwide, and performed over 10 million surgeries.

In October 2021, Da Vinci Innovation Center put in operation in Zhangjiang High-Tech Park, Shanghai.


In August 2022, Da Vinci Surgical Manufacturing R&D Center officially started to be constructed in Shanghai, covering about 31.2 acres.



2.“4+2”Platform



3.Construct a large-scale fully automated assembly line and small-scale POCT clusters around six major therapeutic areas



MEDICAL DIAGNOSIS

In the first half of 2022, Fosun Pharma's medical diagnosis segment actively promoted strategic upgrading and internal integration. In accordance with the business focus and characteristics of each base and subsidiary, Fosun Pharma specified the functions and positioning of each of these bases and subsidiaries as R&D and manufacturing center, differentiated instrument R&D platform, inspection service business platform and reagent manufacturing base, which accelerated the integration and operation integration process of the diagnostic sector, in order to promote the long-term sustainable development of the medical diagnosis segment.

1.Six R&D & Manufacturing Bases





HEALTHCARE SERVICES

In the first half of 2022, the revenue from healthcare services segment reached RMB2,918 million, up by 58.24 % YOY.

In 2021, Fosun Pharma's healthcare service upgraded to build a digital and online healthcare service platform. Taking "medical-grade, full-scenario and one-stop health ecosystem" as the vision and "making families healthier and life better" as the mission, Fosun Health provides users with one-stop healthcare services based on medical-grade trust and closed-loop solutions throughout the treatment course, and becomes a "leader of active family health management".

Offline Healthcare Services

Covered Region	Healthcare Resources	Strong Medical Capability
<ul style="list-style-type: none"> Five major areas, including Pearl River Delta, Yangtze River Delta, Beijing-Tianjin-Hebei Area, Sichuan-Chongqing Area, and the Central of China 5,732 beds in medical institutions controlled by Fosun Pharma by the end of June 2022 	<ul style="list-style-type: none"> 3,000+doctors 30+subsidiary/holding hospitals 220,000+ cooperative doctors 20,000+ cooperative hospitals 	<ul style="list-style-type: none"> 6 Tertiary Hospitals (scale) 8 Secondary Hospitals Top 2 non-public hospital groups in China (Ailibi ranking)

Major Medical Institutions

Pearl River Delta Greater Bay Area


- Foshan Fosun Chancheng hospital**
 - Class III General Hospital with 1,200 beds Received JCI certification
 - TOP1 non-public hospital in China for 4 consecutive years
- Shenzhen Hengsheng Hospital**
 - Class III General Hospital in first-tier city with 600 beds
- The Third Affiliated Hospital of Guangdong Pharmaceutical University (Guangzhou Xinshi Hospital)**
 - Class III General Hospital in the first-tier city with 800 beds

Major Medical Institutions in Other Strategic Region in Other Strategic Regions



Online Healthcare Services

- Since 2021, Fosun Pharma promoted medical internet transformation by actively exploring online and offline integrated service models. A total of 8 Internet Hospital Licenses were obtained by the end of June 2022.
- Fosun Health is committed to building the active health maintenance organization (FHMO) of the Chinese path, taking medical treatment as the core, and creating a medical-grade, full-scenario and one-stop health management platform.



CORPORATE SOCIAL RESPONSIBILITY

Adhering to the ideology of "Innovation For Good Health", Fosun Pharma pursues the sustainable development of talents and products, and actively practices corporate social responsibility, therefore protecting people's health.



Awards & Honors

- Issued corporate social responsibility report for **14** consecutive years

Five-star Rating (Excellent)



- MSCI ESG Rating **A**
- 2022 Fortune China ESG Impact List
- China Top 500 ESG Companies
- 2022 Technology Responsibility · Pioneer 30 Index



- Outstanding Enterprise of Social Responsibility Report in Shanghai
- Outstanding Enterprise in Corporate Social Responsibility and Technology Innovation in "2021 China Benefit Corporation"
- Award for Contribution to the Fight Against COVID-19 2020
- Award for Corporate Responsibility Social Contribution in China 2020

Fosun Pharma Care 121 a Healthcare Initiative, guarding health with responsibility



Developing hand in hand with the Rural Medical Talent Revitalization Program to promote health development in rural areas



In response to the Health China Strategy and Rural Revitalization Strategy, we launched the strategic cooperation of the "Rural Revitalization Health Demonstration Project"



The Future Star Program continues to support education and inspire outstanding teachers and students in universities



Helping Africa fight malaria
Build a malaria-free world



Fighting against the COVID-19 pandemic and safeguarding Shanghai, always on the front-line of the epidemic



Emergency donation of Azvudine tablets to help the frontline of epidemic prevention and control



8 Principles for Fosuners

1 Customer First

Focus on customer needs and help them resolve problems by every means, in order to improve their experience and maximize customer value.

2 Entrepreneurship

Start from value creation; be self-motivated and push beyond your limits; pursue excellence and keep advancing.

3 FC2M Ecosystem Mindset

Proactively understand Fosun's industries, resources and personnel, be good at exploring and integrating internal and external resources from customers' perspectives to realize multiplier effect.

4 Staying Innovative

Embrace change and keep a keen observation of the market; meet customers' needs with innovative thinking and promote continuous evolution of products and organizations.

5 One Step Ahead

Possess strategic foresight and agile execution ability; always stay one step ahead of others in everything.

6 Coopetition

Organization has boundaries while responsibility does not. Stimulate vitality of the organization with healthy competition and achieve the ultimate goal through integration and cooperation.

7 Lifelong Learning

Be humble and pursue lifelong learning; make full use of Fosun's resources to quickly master and digest knowledge and put it into practice.

8 Persistency

Set a fixed course in the right direction; endure the challenges and hardships; make time your friend; never give up until you accomplish your goal.

OUR VALUES



Care for Life

- We respect life, provide safe, convenient and high-quality health products and services and strive to improve the quality of human life.
- We cherish the individual living environment and improve the public health and environment with the idea of sustainable development.
- We are public-spirited, helping poor patients and vulnerable groups, and actively undertake corporate social responsibility .



Continuous Innovation

- We persist in innovation and R&D and bring new possibilities to public health through original breakthroughs and the application of technology improvements.
- We bring together global innovation resources and follow up on cutting-edge R&D technology, to build an international R&D platform.
- We promote management innovation and continuously improve the efficiency of operations, to become a continuously evolving intelligent entity.



Pursuit of Excellence

- We prioritize quality and have established a production management and service system that meets international standards.
- We continuously improve manufacturing processes and optimize service experience, to provide high-quality products and services.
- We pursue excellence and do the right things, the difficult things, and the things taking time to develop.



Sustainable Partnership

- We adhere to the entrepreneurial ideal and advocate entrepreneurship, and advocate the enterprise culture of teamwork.
- We integrate industrial resources and promote integration and synergy, to create value and share development.
- We promote the sustainable development of the industry and create long-term value with excellent partners and strive to build a harmonious and healthy business ecosystem.



FOSUN PHARMA

复星医药



Scan the QR code to
follow our WeChat Official Account



Scan the QR code
to follow our
Wechat Channels



Scan the QR code
to follow our Weibo Official Account

Shanghai Fosun Pharmaceutical (Group) Co., Ltd
Add: Building A, Fosun Hi-Tech Park, No.1289 Yishan Road
Shanghai, P.R.China

Post Code: 200233
Tel: +86-21-33987000
Fax: +86-21-33987020
Our Official Website: www.fosunpharma.com